CYBN:CC News and Press, CYBIN INC. From 06/09/22

A new study that looked into the relationship between an individual’s response to fear and the use of MDMA has found that combining this drug with recall therapy and fear extinction learning substantially decreased the fear felt by individuals involved in the study. This comes after...

New research has found that individuals with symptoms of depression believe that it is crucial that guides who aid in psilocybin-assisted therapy have used the substance themselves. Guides are trained professionals who facilitate the psychedelic experience. Psilocybin is the active compo...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a biotechnology company focused on progressing psychedelic therapeutics, has entered an agreement to acquire the largest phase 1 DMT study conducted to date. The acquisition, conducted through Cybin IRL Limited, a wholly owned subsidiary of Cyb...

-- Acquisition of largest Phase 1 DMT study conducted to date is expected to accelerate CYB004 program timeline by nine months -- -- Phase 1 study evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and will inform clinical path forward -- Cybin ...

A new study has found that more than 30% of individuals in remission from major depressive disorder usually continue experiencing suicidal symptoms , even after the most severe stage of the illness has passed. Major depressive disorder accounts for between 60% and 86% of all suicides. The...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a biotechnology company focused on progressing psychedelic therapeutics, announced that Adelia Therapeutics Inc., its wholly owned subsidiary, has achieved significant milestones, which the company identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Y...

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“ Adelia ”...

Cybin (NEO: CYBN) (NYSE American: CYBN ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced the team of 28 esteemed faculty and advisors ...

Image Cybin Inc. (NEO: CYBN) (NYSE:CYBN), a biopharmaceutical company focused on advancing “psychedelics into therapeutics”, just announced a monumental milestone toward advancing CYB003 into clinical development. CYB003 is a deuterated psilocybin analog desi...